Glp-1 & Gip Drugs:ozempic, Wegovy-Obesity & Diabetes Therapy
Date: 8 September 2025 | Posted by: 0nelove
Glp-1 & Gip Drugs:ozempic, Wegovy-Obesity & Diabetes Therapy
Published 9/2025
MP4 | Video: h264, 1920x1080 | Audio: AAC, 44.1 KHz
Language: English | Size: 446.96 MB | Duration: 0h 51m
Master the science and clinical applications of GLP-1–based therapies like Ozempic, Wegovy, and Mounjaro
What you'll learn
Explain incretin biology and receptor signaling in diabetes and obesity
Differentiate the mechanisms of GLP-1, GIP, and dual agonist therapies
Analyze multi-organ metabolic effects beyond pancreatic regulation
Evaluate clinical data and therapeutic applications of GLP-1–based drugs
Requirements
No prior knowledge required
Description
GLP-1 receptor agonists and dual GIP/GLP-1 agonists have transformed the treatment of type 2 diabetes, obesity, and cardiometabolic disorders. Drugs like Ozempic, Wegovy, and Mounjaro are no longer just glucose-lowering agents; they are reshaping obesity management, cardiovascular risk reduction, and even liver disease therapy.This course is about GLP-1 & GIP Drugs like Ozempic, Wegovy, and Mounjaro used in Obesity & Diabetes Therapy, and is designed to give you a complete, mechanism-driven understanding of how incretin hormones work, why their biology is so powerful, and how modern therapeutics harness these pathways to benefit the people in need. You will explore the molecular mechanisms of incretin receptors, pancreatic regulation, and multi-organ effects, and then connect this knowledge to real-world therapeutic applications.Whether you are in biotech research, pharmacy, medicine, or academia, this course bridges cutting-edge molecular biology with practical pharmacology and clinical insight.By the end, you'll be able to:Explain the physiology of GLP-1 and GIP and their complementary roles in glucose regulationUnderstand how receptor signaling differences translate into therapeutic outcomesEvaluate how incretin therapies impact multiple organs: brain, gut, adipose tissue, and liverAnalyze clinical trial data on HbA1c reduction, weight loss, and cardiovascular protectionAppreciate the evolution from GLP-1 analogues to dual agonists, and where the field is going
Overview
Section 1: Chapter 0 – Introduction: Why GLP-1 Therapies Are Transforming Medicine
Lecture 1 Chapter 0 – Introduction: Why GLP-1 Therapies Are Transforming Medicine
Section 2: Chapter 1 – Incretin Biology and Receptor Signaling in Metabolic Health
Lecture 2 Chapter 1 – Incretin Biology and Receptor Signaling in Metabolic Health
Section 3: Chapter 2 – Comparing GLP-1, GIP, and Dual Agonist Mechanisms
Lecture 3 Chapter 2 – Comparing GLP-1, GIP, and Dual Agonist Mechanisms
Section 4: Chapter 3 – Beyond the Pancreas: Multi-Organ Metabolic Effects
Lecture 4 Chapter 3 – Beyond the Pancreas: Multi-Organ Metabolic Effects
Section 5: Chapter 4 – Clinical Evidence and Therapeutic Applications of GLP-1 Drugs
Lecture 5 Chapter 4 – Clinical Evidence and Therapeutic Applications of GLP-1 Drugs
Biotech and pharmaceutical researchers developing metabolic therapies.,Pharmacy, medical, and life science students seeking therapeutic insights.,Clinicians and pharmacists interested in GLP-1–based treatment strategies.,Healthcare and biotech professionals curious about obesity and diabetes drug innovation.
https://way4share.com/W6g/GLP1_GIP_DrugsOzempic_WegovyObesity_Diabetes_Therapy.rar
https://rapidgator.net/file/fb61bd5278231e360def15e9881e705a/GLP1_GIP_DrugsOzempic_WegovyObesity_Diabetes_Therapy.rar.html
https://rapidgator.net/file/fb61bd5278231e360def15e9881e705a/GLP1_GIP_DrugsOzempic_WegovyObesity_Diabetes_Therapy.rar.html
See full article